AUTHOR=Ragoonanan Dristhi , Khazal Sajad J. , Mejia Rodrigo , Ewing Linette , Durand Jean-Bernard , Bashoura Lara , Tayar Jean , Dailey Garnes Natalie , Petropoulos Demetrios , Tewari Priti , Bhatti Micah , Ahmad Ali Haider , Cortes Jose , Razvi Shehla , McBeth Katrina , Swinford Rita , Shoberu Basirat , Waseemuddin Waseem , Chi Linda , Gill Jonathan B. , Zaky Wafik , Daw Najat , Gutierrez Cristina , Tereffe Welela , Kebriaei Partow , Rezvani Katayoun , Shpall Elizabeth J. , Champlin Richard E. , Mahadeo Kris M. TITLE=Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2 JOURNAL=Frontiers in Oncology VOLUME=11 YEAR=2021 URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.625707 DOI=10.3389/fonc.2021.625707 ISSN=2234-943X ABSTRACT=

Pediatric, adolescent and young adult (AYA) patients receiving novel cancer immunotherapies may develop associated toxicities with overlapping signs and symptoms that are not always easily distinguished from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection/clinical sequelae. We describe 2 diagnostically challenging cases of SARS-CoV-2 and Multi-Inflammatory Syndrome-Adult (MIS-A), in patients with a history of acute lymphoblastic leukemia following cellular therapy administration and review evolving characterization of both the natural course of SARS-CoV-2 infection and toxicities experienced in younger cancer immunotherapy patients. Vigilant monitoring for unique presentations and epidemiologic surveillance to promptly detect changes in incidence of either condition may be warranted.